Article
RAS/CBL mutations predict resistance to JAK inhibitors in myelofibrosis and are associated with poor prognostic features.
Blood advances - 11 Aug 2020
Coltro Giacomo, Rotunno Giada, Mannelli Lara, Mannarelli Carmela, Fiaccabrino Sara, Romagnoli Simone, Bartalucci Niccolò, Ravenda Enrica, Gelli Eleonora, Sant'Antonio Emanuela, Patnaik Mrinal M, Tefferi Ayalew, Vannucchi Alessandro M, Guglielmelli Paola
Abstract excerpt
The dysregulation of the JAK/STAT pathway drives the pathogenesis of myelofibrosis (MF). Recently, several JAK inhibitors (JAKis) have been developed for treating MF. Select mutations (MTs) have been associated with impaired outcomes and are currently incorporated in molecularly annotated prognostic models. Mutations of RAS/MAPK pathway genes are frequently reported in cancer and at low frequencies in MF. In this...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.